Mezigdomide vs TQB3820

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline

Mezigdomide

Developed by Bristol-Myers Squibb

Phase 3 in Multiple Myelomasmall molecule
Partial signal

NCT05552976 · Phase 3 · active, not recruiting

This was a randomized, open-label Phase 3 trial with 606 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-03-09. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.

Next expected readout: November 2026 · NCT03989414 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Up to approximately 5 years): Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09). (met)

Result source: NCT05552976

TQB3820

Developed by Sino Biopharmaceutical

small molecule
Weak signal

NCT05020639 · Phase 1 · status unknown

This is a single-arm, open-label, non-randomized dose-escalation study designed to determine a tolerable dose rather than to test clinical benefit, with no comparator arm and no blinding. Results have not yet been posted. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMezigdomideTQB3820
PFS, median—Trial running · NCT05552976—Not reported
OS, median—Trial running · NCT05552976—Not reported
ORR—Trial running · NCT05552976—Not reported
VGPR or better—Trial running · NCT05552976—Not reported
MRD negativity—Trial running · NCT05552976—Not reported

PFS, median

Mezigdomide
—Trial running · NCT05552976
TQB3820
—Not reported

OS, median

Mezigdomide
—Trial running · NCT05552976
TQB3820
—Not reported

ORR

Mezigdomide
—Trial running · NCT05552976
TQB3820
—Not reported

VGPR or better

Mezigdomide
—Trial running · NCT05552976
TQB3820
—Not reported

MRD negativity

Mezigdomide
—Trial running · NCT05552976
TQB3820
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

TQB3820: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mezigdomide
Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09). NCT05552976 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mezigdomide's landscape · TQB3820's landscape